A new study reveals that the gene PHGDH, previously identified as an Alzheimer's biomarker, directly contributes to the disease by disrupting gene regulation in the brain. Researchers utili…
A new study reveals that the gene PHGDH, previously identified as an Alzheimer's biomarker, directly contributes to the disease by disrupting gene regulation in the brain. Researchers utilized AI to discover PHGDH's hidden DNA-binding function, distinct from its known enzymatic activity, which triggers early Alzheimer's development.
This finding presents a novel therapeutic target for prevention. The team identified a small molecule, NCT-503, that effectively blocks PHGDH's harmful activity without affecting normal brain chemistry. Experiments with mouse models showed that NCT-503 treatment improved memory and reduced anxiety, suggesting its potential for clinical application in Alzheimer's disease.